Acorda Therapeutics

From WikiMD's WELLNESSPEDIA


Logo of Acorda Therapeutics

Acorda Therapeutics is a biotechnology company that develops therapies for neurological disorders. The company is headquartered in Ardsley, New York.

History[edit]

Acorda Therapeutics was founded in 1995 by Ron Cohen, M.D., with the mission to develop therapies that restore function and improve the lives of people with neurological disorders. The company initially focused on developing treatments for spinal cord injury and later expanded its research to include other neurological conditions such as multiple sclerosis (MS) and Parkinson's disease.

Products[edit]

Acorda Therapeutics is known for developing several key products in the field of neurology:

  • Inbrija (levodopa inhalation powder): An inhaled form of levodopa used to treat "off" episodes in patients with Parkinson's disease who are already taking a carbidopa/levodopa regimen. It provides rapid relief from symptoms by delivering levodopa directly to the bloodstream through the lungs.

Research and Development[edit]

Acorda Therapeutics invests heavily in research and development to discover new treatments for neurological disorders. The company's R&D efforts focus on innovative drug delivery systems and novel therapeutic targets. Acorda collaborates with academic institutions and other biotechnology companies to advance its research pipeline.

Corporate Structure[edit]

Acorda Therapeutics operates as a publicly traded company on the NASDAQ stock exchange under the ticker symbol "ACOR." The company is governed by a board of directors and led by a team of executives with extensive experience in the biotechnology and pharmaceutical industries.

Community Involvement[edit]

Acorda Therapeutics is committed to supporting the neurological community through various initiatives. The company sponsors educational programs, patient advocacy groups, and research foundations to raise awareness and improve the quality of life for individuals with neurological disorders.

Related pages[edit]

Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Retrieved from "https://wikimd.org/index.php?title=Acorda_Therapeutics&oldid=6299612"